Loading organizations...
Loading organizations...
MedAware is a technology company.
MedAware provides an AI-powered medication safety monitoring platform designed to identify and mitigate preventable medication-related risks. The company’s technology integrates with existing health data systems to detect potential prescription errors and adverse drug events in real-time, offering comprehensive medication dosage and safety management services. Its core capability lies in leveraging artificial intelligence to create a protective layer within healthcare data workflows.
The company was founded in 2012 by Gidi Stein, Eytan Ruppin, and Tuvik Beker. Their foundational insight stemmed from the need to develop a robust safety net within complex health data systems, aiming to protect both patients and healthcare providers from medication-related incidents. This vision drove the establishment of a system that proactively addresses potential issues before they can manifest.
MedAware primarily serves healthcare professionals and institutions, enabling them to enhance patient care by minimizing medication errors. The company's long-term vision is centered on continuously advancing patient safety through intelligent, real-time medication monitoring, striving for a healthcare environment where medication-related risks are systematically identified and eliminated throughout the entire patient journey.
MedAware has raised $10.0M across 3 funding rounds.
MedAware has raised $10.0M in total across 3 funding rounds.
MedAware has raised $10.0M in total across 3 funding rounds.
MedAware's investors include 500 Global, Catapult Capital, FJ Labs, GIT1K, OurCrowd, Outlander Labs, Practical Venture Capital, Venture Highway, Gourav Bhattacharya, BD, Gefen Capital, Yingcheng City Fubon Technology.
MedAware is a healthcare technology company founded in 2012 that develops an AI-powered medication safety monitoring platform.[1][2][3] The platform integrates with electronic health record (EHR) systems like Epic and athenahealth to continuously monitor patient data, identifying and preventing medication-related risks such as prescription errors, adverse drug events (ADEs), contraindications, and opioid dependency in both inpatient and ambulatory settings.[1][2][3] It serves healthcare providers, hospitals, and patients by providing real-time alerts with high specificity to reduce alert fatigue, improve prescribing behavior, and enhance outcomes, addressing a critical problem where human errors lead to preventable harm and high costs.[1][2][4] At Series A stage with $11.02M raised (last round $8M eight years ago), MedAware reports $4M revenue and deployments like Ballad Health, showing steady growth in clinical decision support.[1][2]
MedAware originated from a tragic incident in Israel where a nine-year-old boy died due to a provider ordering the wrong drug—a human error not caught by existing tools.[5] This spurred a team of physician-scientists and machine learning experts, led by founder Dr. Gidi Stein (a former physician), to create a "safety net" within health data systems.[4][5] Founded in 2012 in Ra'anana, Israel, with a U.S. office in Stamford, Connecticut, the company gained early traction through trials at Sheba Medical Center, Israel's largest hospital, demonstrating reduced mortality risks for alerted patients.[4] Pivotal moments include raising $12M in Series A funding and grants, patent-pending AI tech analyzing EMRs for real-world treatment patterns, and expansions into U.S. integrations.[1][4]
MedAware stands out in clinical decision support through these key strengths:
MedAware rides the wave of AI in healthcare safety, capitalizing on exploding EHR adoption and big data from millions of records to tackle medication errors—a leading cause of patient harm costing billions annually.[1][2][4] Timing aligns with post-pandemic telehealth growth, opioid crises, and regulatory pushes for AI-driven precision medicine, where traditional rule-based alerts overwhelm clinicians.[3][4] Market forces like EHR giants (Epic, athenahealth) seeking add-ons favor its integrations, while Israeli innovation hubs fuel scalable AI exports.[1][2] It influences the ecosystem by setting a standard for proactive, non-intrusive safety layers, inspiring similar AI tools in cybersecurity and climate tech from the region.[1]
MedAware is poised to expand U.S. footprint with more EMR integrations and new ML tools for catastrophic errors, leveraging its live deployments and expert validation to capture value in a $4M revenue base.[1][2][4] Trends like AI regulatory approvals, value-based care, and remote monitoring will accelerate adoption, potentially boosting growth beyond Series A stasis. Its influence may evolve into a foundational safety platform across global health systems, preventing tragedies like the one that birthed it—proving AI's power as the ultimate patient guardian.[3][5]
MedAware has raised $10.0M across 3 funding rounds. Most recently, it raised $8.0M Series A in August 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2017 | $8.0M Series A | 500 Global, Catapult Capital, FJ Labs, GIT1K, OurCrowd, Outlander Labs, Practical Venture Capital, Venture Highway, Gourav Bhattacharya, BD, Gefen Capital, Yingcheng City Fubon Technology | |
| Oct 2, 2014 | $1.0M Series A | Jason Sibley, Jonathan Medved | |
| Oct 1, 2014 | $1.0M Seed | OurCrowd |